Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHWD-870 in Advanced NUT Cancer
NCT06527300Phase 2Recruiting
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NHWD-870 in NUT carcinoma (NC), sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd. Primary endpoint: Objective Response Rate up to 5 months. Started Apr 2024; status: recruiting.
02
Drugs
NHWD-870
03
Conditions
NUT carcinoma (NC)
Beyond the preview
Go deeper on NCT06527300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527300.